Adding Blinatumomab to Standard Treatment for Pediatric B-cell ALL
Children’s Hospital of Philadelphia Research Institute shared a post on LinkedIn:
“Following a Phase 3 study co-led by Children’s Hospital of Philadelphia researchers, children newly diagnosed with B-cell acute lymphoblastic leukemia can now receive an immunotherapy, blinatumomab, as part of their standard treatment plan.
The study, supported by the National Cancer Institute (NCI) and published in the New England Journal of Medicine, was led by the Children’s Oncology Group (COG), of which CHOP is a member.
‘It’s a safe, low-side-effect medication that is going to save a lot of kids’ lives,’ said David Teachey, MD, Chair of COG’s Acute Lymphoblastic Leukemia Disease Committee and Director of Clinical Research at CHOP’s Center for Childhood Cancer Research.
When paired with chemotherapy, blinatumomab increased patients’ three-year, disease-free survival rate from 88% to 96%.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023